Get started

BIOCON

Biocon - At good support zoneHi Traders, As you can see from the above chart, currently BIOCON at good support zone at Rs.347/-, if the tomorrow price took the support at same level you can take the buy trade. You can take the trade after formation of 1 hour candle in the upward direction. You can take the trade at CMP and SL is based on your risk appetite and target is Rs.400 to 420/-. But if the support zone fails to provide the support to price and broke in the downward direction then you can take the short trade ( 1 hour candle should close below the support zone) to take the trade. Based on the price movement you need to assess and take the trade. I will also update about the trade you can check in the trading view under my ID. This analysis is for short term trade and not for Intraday. Note : This is not a financial advice and trade at your own risk. Thank you. Enjoy the trading.
NSE:BIOCONLong
by Sriramulu-Bonagiri
Biocon all set for a gap fillingBIOCON is constantly testing it's resistance level of 423 since it's breakdown of 22nd Jan so any closing of 15 mins candle above 425 will be a massive breakout signal both for intraday and swing traders and it can easily go up for a gap filling. Intraday traders can easily target 1-2% above 425 level. It's a perfect trade since NIFTYPHARMA was seen bullish in last trading session. Also, lockdown fear can be seen in market and we all know that whenever index (NIFTY) goes bearish, NIFTYPHARMA is the only sector that dominates the market so keep a close eye on this script and follow the rules strictly before entering in a trade. *Only for educational purpose*
NSE:BIOCONLong
by anurag0807
$ENTX Entera Bio Ltd Announces Positive Topline EB613 Phase 2Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data ‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21 ‒ The trial’s primary endpoint was met - the complete 3-month results from the trial showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after 3 months of treatment (P <0.04) as compared to placebo. ‒ Similar to the increase in P1NP, a significant increase in Osteocalcin was also observed in the 2.5 mg group after 3 months (P <0.01). ‒ In line with a potential anabolic effect, a significant decrease in CTX was observed after 3 months of treatment (P <0.015). The decrease in CTX taken together with the increase in P1NP and Osteocalcin would indicate a potential positive impact on BMDand a reduced risk of fractures, which is the goal of an anabolic osteoporosis treatment. ‒ Entera intends to submit the full dataset for publication and/or presentation at an upcoming medical conference.
NASDAQ:ENTX
by AlenCiken
Why $EYES Skyrocketed 1233% in March?$EYES Receives FDA Approval for the Argus 2s Retinal Prosthesis System $EYES today announced U.S. FDA has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company expects that the Argus 2s will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System currently under development. In addition to ergonomic improvements, the Argus 2s system offers significantly more processing power, potentially allowing for improved video processing. A decision on when or if to begin production of the newly approved hardware is pending completion of Second Sight’s planned business combination with Pixium Vision, which currently is in progress. Should the business combination be completed, the new management team will then evaluate how best to proceed with the Argus 2s Retinal Prosthesis System, as well as all other products in development. finance.yahoo.com
E
by AlenCiken